AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

AstraZeneca PLC (LON:AZN) has earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is £152.17.

Several research analysts have recently weighed in on the stock. Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 price target on shares of AstraZeneca in a research note on Wednesday, September 2nd. Berenberg Bank reissued a “buy” rating and set a £160 price objective on shares of AstraZeneca in a report on Thursday, September 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a £175 target price on shares of AstraZeneca in a research report on Monday, August 3rd.

AstraZeneca Price Performance

Shares of LON:AZN opened at £118.90 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The stock has a market capitalization of £184.40 billion, a PE ratio of 17.80, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. The firm’s 50 day moving average price is £124.79 and its 200-day moving average price is £136.10. AstraZeneca has a twelve month low of £107.84 and a twelve month high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.